Figure 6.
AMD3100 reduces tumor growth and prolongs survival of mice with metastatic ovarian cancer. (A) Mice were injected intraperitoneally with 1.25 x 105 cells each of HeyA8-CXCL12-CG and NG-CXCR4 cells. After 10 days of tumor growth, mice were imaged for baseline Gaussia luciferase activity immediately before implantation of osmotic infusion pumps with AMD3100 or vehicle control. Repeat imaging studies for Gaussia luciferase complementation were performed on days 5 and 11 of treatment. The fold change in Gaussia luciferase bioluminescence relative to the pretreatment baseline value was determined for each mouse, and mean values for each group ± SEM were graphed. (B) Representative firefly luciferase images for relative numbers of HeyA8-NG-CXCR4 cells before and on days 5 and 11 of treatment with AMD3100 or vehicle control. Scale bar shows pseudocolor display for photon flux values on all images. (C) Quantified data for tumor growth measured by firefly luciferase activity. Fold change in bioluminescence on days 5 and 11 of treatment was determined relative to pretreatment values for each mouse, and data were presented as mean values ± SEM (n = 8 per group). (D) Kaplan-Meier survival curve for mice treated with AMD3100 or vehicle control. Black arrow denotes start of therapy. *P < .05. **P < .01.